Devices running stock Android haven?t exactly been big sellers compared to vendor-customized devices, but a vocal minority continues to clamor for more pure Google experiences. What if users could have the best of both worlds? BGR recently covered custom HTC One software in development that would allow users to switch back and forth between stock Android and HTC?s Sense software at will on the One. Now, that software has been released by MoDaCo as a free public beta and it not only lets users switch back and forth, but it also can share data between the stock Android and Sense builds. This is a custom ROM that requires root access so it isn?t for casual users and installing the software will obviously void your warranty, but experienced users looking for the best of both worlds on one of the most gorgeous smartphones of all time should look no further. All of the files needed to install the new software and a complete installation guide can be found on the MoDaCo site, which is linked below.
DETROIT (AP) ? A person familiar with the deal tells The Associated Press that the Detroit Pistons have acquired point guard Brandon Jennings from the Milwaukee Bucks for point guard Brandon Knight and two prospects.
The person, who spoke Tuesday on condition of anonymity because the trade hasn't been announced, says Jennings has agreed to a $24 million, three-year contract with the Pistons. The person says Detroit will also give up seldom-used center Viacheslav Kravtsov and forward Khris Middleton in the trade.
Detroit has been active this offseason ? signing free agents Josh Smith, Chauncey Billups and Luigi Datome ? as it desperately tries to end its four-year postseason drought.
The Pistons signed Billups to mentor Knight, but have chosen to replace him with Jennings.
NIH launches neurological drug development projectsPublic release date: 31-Jul-2013 [ | E-mail | Share ]
Contact: Christopher Thomas thomaschr@ninds.nih.gov 301-496-5751 NIH/National Institute of Neurological Disorders and Stroke
New projects will target Fragile X syndrome, nicotine addiction, and age-related macular degeneration
The National Institutes of Health has launched three innovative projects that will focus on development of therapeutics for Fragile X syndrome, nicotine addiction, and age-related macular degeneration (AMD). These projects are funded through the NIH Blueprint Neurotherapeutics Network which provides access to a variety of drug development resources.
"We are excited about the opportunity to apply cutting-edge science to the pursuit of novel treatments for these debilitating disorders" said Rebecca Farkas, Ph.D., program director at NIH's National Institute of Neurological Disorders and Stroke (NINDS), Office of Translational Research.
The purpose of the NIH Blueprint is to provide in-depth research capabilities to increase the success rate of innovative drug discovery efforts. The program uses a virtual pharma model to provide researchers with access to support and resources that have been traditionally available to large pharmaceutical companies.
Partnerships between NIH program staff and awarded research teams are designed to bridge the funding gap between ground-breaking laboratory research and industry adoption. NIH staff helps investigators work with veteran industry drug development consultants and contract research organization capabilities from the discovery stage through preliminary clinical trials. In addition, each investigator maintains sole ownership of intellectual property associated with his or her project
NIH launched the Blueprint Neurotherapeutics Network in 2011. Including these three awards, 14 drug discovery programs have been funded as part of the program and 10 are currently active (see: http://neuroscienceblueprint.nih.gov/bpdrugs/bpn.htm).
The newly-funded investigators and their organizations are:
Sage Therapeutics, Cambridge, Mass.
Principal Investigator: Al Robichaud, Ph.D.
Disorder: Fragile X syndrome
Project Summary: Fragile X syndrome is a genetic disorder linked to a range of neurodevelopmental disorders including learning disabilities and cognitive impairment. Many patients experience general and social anxiety yet benzodiazepines, which are drugs typically used to treat anxiety disorders, provide little relief. Their anxiety has been linked to reduced activity in the brain by a protein called, the GABA A receptor. Sage Therapeutics is developing positive allosteric modulators, designed to enhance the receptor's activity and possibly relieve the anxiety.
The Scripps Research Institute, Jupiter, Fla.
Principal Investigator: Paul J. Kenny, Ph.D.
Disorder: nicotine addiction
Project Summary: Nicotine addiction has been attributed to the stimulatory effects of nicotine binding to brain proteins called orexin 1 receptors. Dr. Kenny and colleagues will develop selective receptor antagonists as potential smoking cessation aids to treat people who have attempted to quit smoking but faced high relapse rates and significant side effects.
University of Utah, Salt Lake City
Principal Investigator: Dean Yaw Li, Ph.D.
Disorder: age-related macular degeneration
Project Summary: Age-related macular degeneration is a leading cause of blindness in the United States. One form, called wet AMD, is associated with inflammation and blood vessel leakage in the retina, the eye's light-sensitive tissue. Dean Li and his colleagues are developing small molecules that inhibit the activity of Arf6, a molecule known to help control inflammation and blood vessel leakage. This novel approach may lead to effective therapies for treating patients who do not respond to current wet AMD therapies.
###
NINDS is the nation's leading funder of research on the brain and nervous system. The NINDS mission is to reduce the burden of neurological disease a burden borne by every age group, by every segment of society, by people all over the world.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
NIH launches neurological drug development projectsPublic release date: 31-Jul-2013 [ | E-mail | Share ]
Contact: Christopher Thomas thomaschr@ninds.nih.gov 301-496-5751 NIH/National Institute of Neurological Disorders and Stroke
New projects will target Fragile X syndrome, nicotine addiction, and age-related macular degeneration
The National Institutes of Health has launched three innovative projects that will focus on development of therapeutics for Fragile X syndrome, nicotine addiction, and age-related macular degeneration (AMD). These projects are funded through the NIH Blueprint Neurotherapeutics Network which provides access to a variety of drug development resources.
"We are excited about the opportunity to apply cutting-edge science to the pursuit of novel treatments for these debilitating disorders" said Rebecca Farkas, Ph.D., program director at NIH's National Institute of Neurological Disorders and Stroke (NINDS), Office of Translational Research.
The purpose of the NIH Blueprint is to provide in-depth research capabilities to increase the success rate of innovative drug discovery efforts. The program uses a virtual pharma model to provide researchers with access to support and resources that have been traditionally available to large pharmaceutical companies.
Partnerships between NIH program staff and awarded research teams are designed to bridge the funding gap between ground-breaking laboratory research and industry adoption. NIH staff helps investigators work with veteran industry drug development consultants and contract research organization capabilities from the discovery stage through preliminary clinical trials. In addition, each investigator maintains sole ownership of intellectual property associated with his or her project
NIH launched the Blueprint Neurotherapeutics Network in 2011. Including these three awards, 14 drug discovery programs have been funded as part of the program and 10 are currently active (see: http://neuroscienceblueprint.nih.gov/bpdrugs/bpn.htm).
The newly-funded investigators and their organizations are:
Sage Therapeutics, Cambridge, Mass.
Principal Investigator: Al Robichaud, Ph.D.
Disorder: Fragile X syndrome
Project Summary: Fragile X syndrome is a genetic disorder linked to a range of neurodevelopmental disorders including learning disabilities and cognitive impairment. Many patients experience general and social anxiety yet benzodiazepines, which are drugs typically used to treat anxiety disorders, provide little relief. Their anxiety has been linked to reduced activity in the brain by a protein called, the GABA A receptor. Sage Therapeutics is developing positive allosteric modulators, designed to enhance the receptor's activity and possibly relieve the anxiety.
The Scripps Research Institute, Jupiter, Fla.
Principal Investigator: Paul J. Kenny, Ph.D.
Disorder: nicotine addiction
Project Summary: Nicotine addiction has been attributed to the stimulatory effects of nicotine binding to brain proteins called orexin 1 receptors. Dr. Kenny and colleagues will develop selective receptor antagonists as potential smoking cessation aids to treat people who have attempted to quit smoking but faced high relapse rates and significant side effects.
University of Utah, Salt Lake City
Principal Investigator: Dean Yaw Li, Ph.D.
Disorder: age-related macular degeneration
Project Summary: Age-related macular degeneration is a leading cause of blindness in the United States. One form, called wet AMD, is associated with inflammation and blood vessel leakage in the retina, the eye's light-sensitive tissue. Dean Li and his colleagues are developing small molecules that inhibit the activity of Arf6, a molecule known to help control inflammation and blood vessel leakage. This novel approach may lead to effective therapies for treating patients who do not respond to current wet AMD therapies.
###
NINDS is the nation's leading funder of research on the brain and nervous system. The NINDS mission is to reduce the burden of neurological disease a burden borne by every age group, by every segment of society, by people all over the world.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Congressional Republicans are fighting Obama's plan to put a base on the moon and use it to launch an asteroid-capture program which would give NASA some practice in deflecting future asteroid-strikes -- as well as setting the stage for more ambitious missions, such as one to Mars. This whole kerfuffle was predicted by the Onion, two years ago, in a story called "Republicans Vote To Repeal Obama-Backed Bill That Would Destroy Asteroid Headed For Earth."
The Onion, one of America's leading satirical news outlets, has predicted the future before. Al Qaeda squabbling with 9/11 truthers, for instance. Or the Onion's piece on George W. Bush ushering in an era of war and economic recession...published in January 2001.
The Onion Predicts Real Life: Republicans Block NASA's Asteroid Plan
[Asawin Suebsaeng/Christian Science Monitor]
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_t-VR3GQu0gF2mB7ls15-yLHwTCK3lLlIih6bd6ZJmzs_HvhFIOAhUmNLtUyrTKa_Ryb4YqexY9o2yFnTKosrxv9XfbQgdJ77YaSGJwrvA=s0-d){kind=small}
Public release date: 31-Jul-2013
Share ] 